Selecting the Best Brain Tumour Surgeons and Hospitals in India for Australian Patients

Author:- Dr. Dheeraj Bojwani Date Created:- 14-08-2026

Most Australians should never need this guide, and I want to say that plainly before anything else. Australian neurosurgery is genuinely excellent, close to free at the point of use through Medicare, and moving primary treatment overseas is rarely the right answer. This guide exists for a narrower group — and it is worth being precise about who that is before a single criterion is discussed. In 24 years of guiding international patients into Indian hospitals, I have turned away more Australians with brain tumours than from almost any other diagnosis, and I would do it again tomorrow. If none of the four reasons above describes your situation, the right next step is a conversation with your Australian neurosurgical team, not this document.

Healing Journeys of Australian Patients

Australian Patients Share Their Experience

Key Takeaways

• The guide first stresses that most Australian patients should not automatically move brain tumour treatment overseas. Australia has strong neurosurgical services, and an Indian opinion is mainly considered for selected situations.
• Page 1 identifies four situations where an Australian patient may consider an Indian specialist: a second opinion after an “inoperable” assessment, a rare tumour requiring a higher-volume centre, access to fluorescence-guided or awake-mapping surgery, or a faster private surgical pathway.
• Before contacting an Indian centre, patients should have their MRI series, biopsy pathology and written Australian neurosurgical assessment ready. The guide stresses that operability can be a matter of expert judgement.
• The weighted chart gives the greatest emphasis to neuro-oncology/skull-base fellowship (14 points), fluorescence guidance and awake mapping (13), molecular pathology (12) and tumour-specific surgical volume (11).
• The qualification table explains the pathway from MBBS to MS/DNB, MCh/DrNB Neurosurgery and finally fellowship in neuro-oncology or skull-base surgery, with the fellowship identified as particularly relevant to complex brain tumour surgery.
• The technology chart presents an illustrative comparison of approximately 62% gross total resection with standard microsurgery versus approximately 89% with fluorescence guidance and neuronavigation in the cited literature pattern. The guide advises patients to confirm whether these technologies will actually be used for their specific tumour.
• Hospital selection should include on-site molecular pathology, multidisciplinary tumour-board review, neuronavigation and intraoperative imaging, a dedicated neuro-ICU and complete records that the Australian team can use.
• The guide identifies four warning signs: a quotation before imaging review, a firm operability verdict without multidisciplinary review, vague tumour-specific surgical volume and unsupported claims of a cure.
• The pathway shows six stages: send imaging and pathology → video consultation with the operating surgeon → written itemised quote → travel and pre-operative workup → surgery and tumour-board review → records returned to the Australian team.
• Australian patients should inform their Australian neurosurgical team early, arrange ongoing care before leaving, send the actual imaging rather than only reports and ask whether the Medical Treatment Overseas Program could apply in circumstances where a specific technique is unavailable in Australia.
• Australian patients should also clarify what happens if the diagnosis changes after surgery, including who will manage subsequent radiotherapy or oncology treatment.
• The final checklist asks Australian patients to verify surgeon fellowship, tumour-specific experience, technology use, resection-versus-function judgement, molecular pathology, accreditation, neuro-ICU availability, complication coverage and the final operative/pathology record.

Quick Facts

Treatment

Brain Tumour Surgery

Country

India

Patients

Australian Patients

Main Indications

Second Opinion, Rare Tumours, Advanced Surgical Technology and Faster Private Pathway

Key Specialist

Neuro-Oncology / Skull-Base Neurosurgeon

Top Selection Criterion

Neuro-Oncology or Skull-Base Fellowship

Important Technology

Fluorescence Guidance, Neuronavigation and Awake Mapping

Tumour-Specific Volume

Should be confirmed for the exact tumour type and location

Molecular Testing

IDH, MGMT and 1p/19q where relevant

Multidisciplinary Review

Neuro-radiology, neuro-oncology, pathology and neurosurgery

Hospital Requirement

Dedicated Neuro-ICU

Important Infrastructure

Intraoperative imaging and neuronavigation

Accreditation

JCI or NABH can be verified

Pre-Travel Records

MRI, pathology and Australian neurosurgical assessment

Follow-Up

Australian Neurosurgical / Oncology Team

Important Check

Written itemised quotation and complication coverage

Visa

Medical e-visa and attendant visa options for eligible Australian passport holders

Author

Dr. Dheeraj Bojwani

Experience

24+ Years

In Brief

For Australian patients considering brain tumour surgery in India, the guide recommends beginning with the diagnosis rather than with hospital or surgeon marketing. Actual MRI images, pathology and molecular information should be reviewed before any decision about operability or cost. The strongest selection criteria are tumour-specific surgical experience, neuro-oncology or skull-base fellowship, appropriate use of fluorescence guidance, neuronavigation and awake mapping, and multidisciplinary review. Hospital infrastructure also matters, particularly molecular pathology, neuro-ICU support and complete postoperative documentation. The guide repeatedly emphasises that an overseas second opinion should complement—not replace—the Australian neurosurgical team's care and that urgent neurological symptoms require immediate assessment in Australia.

Before you choose anyone: get the diagnosis pinned down at home

Every criterion below depends on one thing being settled first: full imaging and, where a biopsy has been done, a confirmed histological and molecular diagnosis, obtained in Australia, where Medicare pays for it. A surgeon anywhere in the world can only be as good as the imaging and pathology he or she is working from.

Get your MRI series, any prior biopsy pathology, and a written note on what your Australian neurosurgeon considered and why, before your first overseas conversation. This matters because operability itself is genuinely a matter of expert judgement, not always a fixed fact — a second opinion at a high-volume centre occasionally changes that judgement, and that is a legitimate, well-established reason to seek one.

This is worth taking seriously rather than treating as a formality. Brain tumours cover a genuinely wide range of conditions, from meningiomas that are usually benign and frequently cured with surgery alone, through to higher-grade gliomas where the treatment calculus is more complex. Knowing precisely which category your tumour falls into, confirmed by tissue and imaging rather than assumption, changes every criterion that follows.

Part one: judging the surgeon and the neurosurgical team

1. Fellowship in neuro-oncology or skull-base surgery. A general neurosurgeon who occasionally operates on tumours is not the same as one who has completed specific further training in this area. Ask directly what fellowship was completed, where, and in which year.

2. Fluorescence guidance and neuronavigation, genuinely used. Ask specifically whether 5-ALA fluorescence guidance, neuronavigation and, where relevant, awake mapping will be used for your specific tumour, not just whether the hospital owns the equipment. Fluorescence guidance uses a compound taken before surgery that causes high-grade tumour tissue to glow under specific light, letting a surgeon see margins that are otherwise invisible to the naked eye. Neuronavigation tracks instruments against pre-operative imaging in real time, accurate to a millimetre. Together, these tools change what a surgeon can safely see and remove, and their absence, or their presence but non-use for your specific case, is worth asking about directly rather than assuming.

3. Volume in your specific tumour type. Not general neurosurgery, not tumour surgery in aggregate — the number of operations performed last year on your specific tumour type and location. Ask for the figure in writing.

4. Honest resection-versus-function judgement. A more aggressive resection is not always the right goal, particularly near critical structures. A genuinely experienced surgeon discusses this trade-off directly rather than promising maximal resection regardless of location. For tumours near speech, motor or other critical areas, ask specifically whether awake craniotomy with intraoperative mapping is used, and how frequently. This technique allows a surgical team to test and protect essential function in real time during the operation itself, and its availability is a genuine marker of a team equipped for technically demanding cases near eloquent brain regions.

5. Personally operates, and speaks to you first. Insist on a video consultation with the surgeon who will actually operate, not a coordinator, before any deposit moves.

Part two: judging the hospital

6. Molecular pathology on site. IDH mutation status, MGMT methylation and 1p/19q co-deletion, where relevant, are central to accurate diagnosis under current classification standards. Ask whether this is performed in-house and what the turnaround time is.

7. A tumour board including neuro-radiology. Ask whether your case will be reviewed by a genuine multidisciplinary team before and after surgery, not decided by one surgeon alone. A genuine multidisciplinary review brings neurosurgery, neuro-radiology, neuro-oncology and pathology together on your specific case, and it should happen both before surgery, to confirm the plan, and afterward, once full pathology is available, to determine what follow-up treatment is needed.

8. Neuronavigation and intraoperative imaging genuinely available. Confirm the specific technology, not a general claim of “advanced facilities”.

9. Neuro-ICU depth. Ask whether a dedicated neurosurgical ICU is available and who manages medical complications if they arise.

10. A record your Australian team can act on. Before you leave you should hold the full operative note, complete pathology including molecular results, and a specific follow-up plan.

What the quote should say, and what it usually omits

In 24 years I have found that disputes almost never concern the quoted price. They concern what the quote silently omitted.

Insist on a written, itemised figure that states what happens if the plan changes intraoperatively, and what that would cost. Ask what the hospital covers if a complication requires extended ICU care. Understand what does not travel with you: Medicare pays nothing for treatment overseas, your health fund rebate applies to Australian admissions, and standard travel insurance excludes planned surgery and its complications. Pay a deposit to secure the date, never the full balance in advance.

Four Signals that Should Make You Pause

1. A price quoted before your imaging has been reviewed. Nobody can price brain tumour surgery they have not seen the scans for.

2. A firm operability verdict given before a multidisciplinary review. This decision should never rest on one surgeon's read of a scan alone.

3. Vagueness about volume in your specific tumour type. General reassurance is not an answer; hesitation on the specific number is itself information.

4. Any claim of a cure your Australian neurosurgeon has not heard of. Legitimate neurosurgery has no need to oversell itself.

Australia-specific considerations most patients miss

Tell your Australian neurosurgical team early, not after the fact. Most are more sympathetic to a second opinion than patients expect, and a team informed from the outset is better placed to pick up your care afterwards.

Arrange your ongoing care before you leave. If radiotherapy or further oncology treatment may follow, confirm your Australian team is willing to deliver it based on overseas surgical findings.

Send the imaging, not just the report. A second opinion requires the actual scans, not a typed summary.

Ask about the Medical Treatment Overseas Program. Where a specific technique is genuinely unavailable in Australia, this Commonwealth programme can in some circumstances fund treatment abroad.

Apply for both visas together. Australian passport holders are eligible for India's electronic medical visa, with an e-medical attendant visa for whoever travels with you.

Ask what happens if the diagnosis changes after surgery. Establish the plan before you travel, and ask an Australian neurosurgeon the parallel question directly.

The Questions, in the Order You Should Ask Them

A closing word

Brain tumour surgery rewards precision more than almost any decision in this series. If your situation is a second opinion, a rare tumour, access to specific technology or a faster private option — verify the diagnosis first, weight fellowship training and genuine technology use as heavily as volume, and ask about the resection-versus-function trade-off before anything else. If you would like a second opinion on your imaging, send it and I will look at it properly — including telling you that your case should stay in Australia, which is an answer I give often.

Frequently Asked Questions by Australians about Brain Tumour Surgeons and Hospitals in India

Should Australian patients automatically travel to India for brain tumour surgery?

No. The guide specifically states that most Australian patients should continue treatment with their Australian neurosurgical team. India may be considered for selected Australian patients seeking a second opinion, rare-tumour expertise, specific technology or a faster private pathway.

What should Australian patients send to an Indian brain tumour surgeon for a second opinion?

Australian patients should send their actual MRI imaging, previous biopsy pathology and written assessment from their Australian neurosurgeon. The guide stresses that a typed imaging report alone is not sufficient for a meaningful surgical second opinion.

What specialist qualification should Australian patients look for in an Indian brain tumour surgeon?

The guide recommends looking beyond general neurosurgical training and specifically checking for a fellowship in neuro-oncology or skull-base surgery. Patients should ask where and when the fellowship was completed.

Should Australian patients ask whether fluorescence guidance will actually be used during their surgery?

Yes. Australian patients should ask whether 5-ALA fluorescence guidance, neuronavigation and, where appropriate, awake mapping will actually be used for their particular tumour. Merely having the equipment in the hospital is not enough.

How should Australian patients assess a surgeon's brain tumour experience?

They should ask for the number of operations performed on their exact tumour type and location, rather than relying on the surgeon's overall neurosurgical or cancer-surgery volume. The guide recommends asking for this figure specifically.

What should Australian patients ask about molecular testing before brain tumour surgery in India?

They should ask whether IDH mutation, MGMT methylation and 1p/19q co-deletion testing, where relevant, is performed on site and what the expected turnaround time is. These results can be important for accurate tumour classification and subsequent treatment planning.

Should Australian patients accept a diagnosis of an “inoperable” brain tumour without seeking another opinion?

The guide explains that operability can involve expert judgement and is not always an absolute fixed fact. For an Australian patient who has been told a tumour is inoperable, a second opinion from an appropriate high-volume specialist centre may therefore be worth considering.

What hospital facilities should Australian patients verify before brain tumour surgery in India?

Australian patients should verify molecular pathology, multidisciplinary tumour-board review, neuronavigation or intraoperative imaging and a dedicated neuro-ICU. They should also confirm what support is available if complications require extended care.

What should Australian patients check before accepting a brain tumour surgery quotation from India?

They should first ensure that the Indian team has reviewed the actual imaging and diagnosis. The guide recommends a written, itemised quotation explaining what happens if the surgical plan changes and what additional costs may arise from complications or extended ICU care.

How should Australian patients arrange follow-up after brain tumour surgery in India?

Australian patients should involve their Australian neurosurgical team before travelling and establish who will provide ongoing care after returning home. They should leave India with the complete operative record, final pathology including molecular results and a specific follow-up plan that their Australian team can act on.

Sources

• Published neurosurgical literature on fluorescence-guided resection and extent-of-resection outcomes — pubmed.ncbi.nlm.nih.gov
• National Medical Commission, recognised postgraduate medical qualifications in neurosurgery — nmc.org.in
• Australian Government Medical Treatment Overseas Program, eligibility criteria — health.gov.au
• Joint Commission International, accreditation registers — jointcommissioninternational.org
• National Accreditation Board for Hospitals & Healthcare Providers, accreditation registers — nabh.co
• High Commission of India, e-Visa categories and eligibility — indianvisaonline.gov.in

Page Summary

This guide helps Australian patients understand when a brain tumour second opinion or surgery in India may be appropriate. It stresses confirming imaging, pathology and molecular diagnosis before making treatment decisions. It explains how fellowship training, tumour-specific experience, fluorescence guidance and neuronavigation can help in selecting a surgeon. It also highlights tumour-board review, molecular pathology and dedicated neuro-ICU facilities. The guide identifies warning signs to consider before accepting a recommendation or quotation. It concludes with the treatment pathway and planning for continued care with the Australian medical team.

Citation Block

Field	Information
Topic Information	Selecting the Best Brain Tumour Surgeons and Hospitals in India for Australian Patients
Treatment	Brain Tumour Surgery
Country	India
Intended Audience	Australian Patients
Main Reasons for Overseas Opinion	Second Opinion, Rare Tumour, Advanced Technology or Faster Private Pathway
Key Specialist Training	Neuro-Oncology / Skull-Base Fellowship
Important Technology	Fluorescence Guidance, Neuronavigation and Awake Mapping
Tumour-Specific Experience	Confirm exact annual surgical volume
Molecular Pathology	IDH, MGMT and 1p/19q where relevant
Multidisciplinary Review	Neurosurgery, Neuro-radiology, Neuro-oncology and Pathology
Hospital Requirement	Dedicated Neuro-ICU
Accreditation	JCI or NABH
Initial Records	MRI, Biopsy Pathology and Australian Neurosurgical Assessment
Treatment Pathway	Imaging → Consultation → Quote → Workup → Surgery → Records
Important Warning	Avoid pricing before imaging review
Follow-Up	Coordinate with Australian Neurosurgical / Oncology Team
Visa	Medical e-visa and attendant visa options
Final Records	Operative note, complete pathology and follow-up plan